American Capital pumps $66m into Avalon:
This article was originally published in Clinica
Executive Summary
Avalon Laboratories, a privately-held supplier of cardiopulmonary vascular cannulae, has received a $66m investment from American Capital Strategies. The funds, which will be used to drive Avalon's growth, was provided in the form of a senior term loan, senior subordinated debt and convertible preferred and common equity. American Capital is also providing Rancho Dominguez, California-based Avalon with a revolving credit facility. Avalon claims to manufacture over a third of all cannulae used globally. Its products are used to link patients up with life support machines.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.